|Bid||65.64 x 800|
|Ask||65.65 x 1100|
|Day's range||63.66 - 65.92|
|52-week range||57.17 - 74.12|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||11.22|
|Earnings date||27 Apr 2022 - 02 May 2022|
|Forward dividend & yield||2.92 (4.89%)|
|Ex-dividend date||14 Jun 2022|
|1y target est||69.48|
Yahoo Finance Live’s Brad Smith breaks down how stocks are moving in early trading.
FOSTER CITY, Calif., August 15, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced statistically significant and clinically meaningful results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. Detailed OS results will be pres
If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.